Message #25 From:
NewsBot Date: March 6, 2007 09:43:00 AM
EGEI News eGene Receives Notice of Allowance from US Patent Office for Patent Application 'MULTI-SEGMENT CARTRIDGE FOR BIO-SEPARATION WITH MULTIPLEXED FLUORESCENCE DETECTION'
IRVINE, Calif.--(BUSINESS WIRE)--eGene Inc. (OTCBB:EGEI), a leading biotechnology company and developer of a compact and automated digital genetic analyzer, announced today that the Company has received notice of allowance from the US Patent Office of its decision to grant a patent for the "MULTI-SEGMENT CARTRIDGE FOR BIO-SEPARATION WITH MULTIPLEXED FLUORESCENCE DETECTION." This marks the Company's 7th US patent and 10th patent worldwide.
This key patent is one of a series of pending patent applications that significantly broadens eGene's proprietary position in the genomic testing and bioinformatics markets.
"Receiving a patent that provides a simplified, low cost, high efficient and high throughput detection method that overcomes the drawback of the prior art is so fundamentally essential to our success in the rapidly growing genotyping market, where it reinforces our path to a leadership position in the industry,” explained by the co-inventor Mr. Varouj Amirkhanian, who is the Executive V.P. & R&D Director at eGene.
Dr. Ming Liu, Chief Executive Officer & co-inventor, said, “We believe our patented technology will play a leading role in the evolution of the molecular diagnostics market as personalized medicine becomes mainstream. Our recently-launched revolutionary automatic HLA-SSP genotyping system for bone marrow genotype matching is capturing great market attention. There is a real market need for cost-effective solutions while still producing high quality results.”
About eGene Inc.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. eGene developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels). The system analyzes the genetic fingerprints of living organisms. It performs fast DNA sample screening, genotyping analysis, gene expression to replace the current slab gel electrophoresis tools. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.
